Sukhbir Kaur1, Tiffany Chang1, Satya P Singh2, Langston Lim3, Poonam Mannan3, Susan H Garfield3, Michael L Pendrak1, David R Soto-Pantoja1, Avi Z Rosenberg1, Shelly Jin1, David D Roberts4. 1. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20982; 2. Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20982; and. 3. Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. 4. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20982; droberts@helix.nih.gov.
Abstract
Thrombospondin-1 (TSP1) inhibits angiogenesis, in part, by interacting with the ubiquitous cell-surface receptor CD47. In endothelial cells, CD47 interacts directly with vascular endothelial growth factor receptor (VEGFR)-2, and TSP1 inhibits VEGFR2 phosphorylation and signaling by disrupting this association. We show that CD47 similarly associates with and regulates VEGFR2 in T cells. TSP1 inhibits phosphorylation of VEGFR2 and its downstream target Src in wild type but not in CD47-deficient human Jurkat and primary murine T cells. VEGFR2 signaling inhibits proliferation and TCR signaling in wild type T cells. However, ligation of CD47 by TSP1 or loss of CD47 expression reverses some inhibitory effects of VEGF on proliferation and T cell activation. We further found that VEGF and VEGFR2 expression are upregulated in CD47-deficient murine CD4(+) and human Jurkat T cells, and the resulting autocrine VEGFR2 signaling enhances proliferation and some TCR responses in the absence of CD47. Thus, CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of VEGF by T cells contributes to this regulation. This provides a mechanism to understand the context-dependent effects of TSP1 and VEGF on T cell activation, and reveals an important role for CD47 signaling in regulating T cell production of the major angiogenic factor VEGF.
Thrombospondin-1 (n class="Gene">TSP1) inhibits angiogenesis, in part, by interacting with the ubiquitous cell-surface receptor CD47. In endothelial cells, CD47 interacts directly with vascular endothelial growth factor receptor (VEGFR)-2, and TSP1 inhibits VEGFR2 phosphorylation and signaling by disrupting this association. We show that CD47 similarly associates with and regulates VEGFR2 in T cells. TSP1 inhibits phosphorylation of VEGFR2 and its downstream target Src in wild type but not in CD47-deficienthumanJurkat and primary murine T cells. VEGFR2 signaling inhibits proliferation and TCR signaling in wild type T cells. However, ligation of CD47 by TSP1 or loss of CD47 expression reverses some inhibitory effects of VEGF on proliferation and T cell activation. We further found that VEGF and VEGFR2 expression are upregulated in CD47-deficientmurineCD4(+) and humanJurkat T cells, and the resulting autocrine VEGFR2 signaling enhances proliferation and some TCR responses in the absence of CD47. Thus, CD47 signaling modulates the ability of VEGF to regulate proliferation and TCR signaling, and autocrine production of VEGF by T cells contributes to this regulation. This provides a mechanism to understand the context-dependent effects of TSP1 and VEGF on T cell activation, and reveals an important role for CD47 signaling in regulating T cell production of the major angiogenic factor VEGF.
Authors: Heba O Barazi; Zhuqing Li; Jo Anne Cashel; Henry C Krutzsch; Douglas S Annis; Deane F Mosher; David D Roberts Journal: J Biol Chem Date: 2002-09-05 Impact factor: 5.157
Authors: Zhuqing Li; Maria J Calzada; John M Sipes; Jo Anne Cashel; Henry C Krutzsch; Douglas S Annis; Deane F Mosher; David D Roberts Journal: J Cell Biol Date: 2002-04-29 Impact factor: 10.539
Authors: Pulak Ranjan Nath; Dipasmita Pal-Nath; Ajeet Mandal; Margaret C Cam; Anthony L Schwartz; David D Roberts Journal: Cancer Immunol Res Date: 2019-07-30 Impact factor: 11.151
Authors: Sukhbir Kaur; Abdel G Elkahloun; Satya P Singh; Anush Arakelyan; David D Roberts Journal: J Cell Commun Signal Date: 2017-11-29 Impact factor: 5.782
Authors: Patrick Coit; Paul Renauer; Matlock A Jeffries; Joan T Merrill; W Joseph McCune; Kathleen Maksimowicz-McKinnon; Amr H Sawalha Journal: J Autoimmun Date: 2015-05-23 Impact factor: 7.094
Authors: David R Soto-Pantoja; Masaki Terabe; Arunima Ghosh; Lisa A Ridnour; William G DeGraff; David A Wink; Jay A Berzofsky; David D Roberts Journal: Cancer Res Date: 2014-10-08 Impact factor: 12.701